Early studies focused on pathophysiology comparing gram positive and gram negative organisms, the role of endotoxemia, and the efficacy of anti-endotoxin therapies such as lipid A analogs and antibodies.? ? Nitric oxide was examined as an important mediator of septic shock. Non-selective nitric oxide synthase inhibitors were sometimes toxic and never beneficial.? ? Normal volunteers challenged with endotoxin were found to release increased amounts of nitric oxide. Although ibuprofen blocked endotoxin-induced increases in nitric oxide production, blood pressure was unaffected, suggesting that other mechanisms compensated to maintain vasodilation.? ? Severity of illness (risk of death) was found to influence the therapeutic efficacy of anti-inflammatory agents in septic shock. This finding was used by the FDA to re-analyze the PROWESS trial of rhAPC (Xigris) and led to initial approval only for patients with a high risk of death. The lack of rhAPC efficacy in patients with a low risk of death was confirmed in the ADDRESS trial.? ? The administration of L-arginine without or with N-acetylcysteine in a canine model of septic shock was found to be harmful. L-arginine is a common component of immunonutrition formulas that are marketed for use in critically ill patients.? ? Intra-aortic balloon counterpulsation was found to prolong survival in a hypodynamic canine model of Staphylococcus aureas pneumonia induced septic shock.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL008060-05
Application #
7593067
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2007
Total Cost
$130,799
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Moriyama, Brad; Henning, Stacey A; Neuhauser, Melinda M et al. (2009) Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother 43:1324-37
Cobb, J; Ognibene, Frederick; Ingbar, David et al. (2009) Forging a critical alliance: Addressing the research needs of the United States critical illness and injury community* Crit Care Med :
Eichacker, Peter Q; Natanson, Charles; Danner, Robert L (2007) Separating practice guidelines from pharmaceutical marketing. Crit Care Med 35:2877-8;author reply 2878-80
Deans, Katherine J; Minneci, Peter C; Suffredini, Anthony F et al. (2007) Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols. Crit Care Med 35:1509-16
Minneci, Peter C; Deans, Katherine J; Hansen, Bernie et al. (2007) A canine model of septic shock: balancing animal welfare and scientific relevance. Am J Physiol Heart Circ Physiol 293:H2487-500
Eichacker, Peter Q; Natanson, Charles; Danner, Robert L (2006) Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 355:1640-2
Solomon, Steven B; Cui, Xizhong; Gerstenberger, Eric et al. (2006) Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis 193:634-44
Kalil, Andre C; Danner, Robert L (2006) L-Arginine supplementation in sepsis: beneficial or harmful? Curr Opin Crit Care 12:303-8
Sevransky, Jonathan; Vandivier, R William; Gerstenberger, Eric et al. (2005) Prophylactic high-dose N(omega)-monomethyl-L-arginine prevents the late cardiac dysfunction associated with lethal tumor necrosis factor-alpha challenge in dogs. Shock 23:281-8
Haley, Michael; Parent, Chantal; Cui, Xizhong et al. (2005) Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model. J Appl Physiol 98:2155-62

Showing the most recent 10 out of 18 publications